Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

Millennium Pharmaceutical’s year in review

Home/Research, Supplements/Drugs/Millennium Pharmaceutical’s year in review

Millennium Pharmaceutical’s year in review

I wanted to share some excerpts from a sort of “year in review” interview with Dr. Deborah Dunsire, CEO of Millennium Pharmaceuticals, makers of Velcade.  I found this article on a site called Mass High earlier this month:

Millennium reports myeloma drug advances, updates drug recalls

By Lori Valigra, Mass High Tech correspondent

Cambridge:  The Takeda Oncology is reporting advances in its drugs for multiple myeloma, and said it is adding manufacturing suppliers in the wake of a series of precautionary recalls for its Velcade treatment in the United States and Europe…

…CEO Deborah Dunsire told Mass High Tech that the company continues to increase the uses of Velcade both by cancer type and by indication.  “The excitement for patients here is there are now therapies that extend their lives,” Dunsire said. “It’s best to use this first. It truly makes a different in outcomes.”

According to Lori Valigra’s article, Millennium continues to increase the uses of Velcade both by cancer type and by indication. At the American Society of Hematology (ASH) meeting today in San Diego, Calif., Millennium is releasing a new five-year follow up of overall survival data on Velcade demonstrating a significant impact on extending the lives of multiple myeloma (MM) patients.

The data show that Velcade-based therapy resulted in a statistically significant 13.3 month increase in the median chance of survival across all MM patient subgroups, including those 75 years and older, and a 31 percent reduced risk of death. The data also suggest that Velcade should be given first for newly diagnosed, previously untreated MM patients, as those who received Velcade as first line treatment in the trial showed greater chance of survival than those who received it or other therapies in subsequent treatments during the five year follow-up.

Simply CLICK HERE to read more, including an update about MLN9708, a new oral proteasome inhibitor for patients with relapsed and/or refractory multiple myeloma.

Feel good and keep smiling!  Pat